Britain Backs GSK’s Gene Therapy for ‘Bubble Boy’ Syndrome

October 24, 2017

(Reuters) – GlaxoSmithKline’s gene therapy for the so-called “bubble boy” disease was approved by Britain’s healthcare cost watchdog NICE, despite a price tag of almost 600,000 euros ($700,000). Gene therapy is designed to deliver a one-off cure for the patient and drugmakers are typically asking a hefty price that is comparable to the combined costs of alternative life-long treatment.

Recommended Reading